Table 2.
Connectivity | Strength | P | |
---|---|---|---|
Decreased by VPA treatment | VPA-treated | Control | |
Olfactory bulb (IC38) ↔ nucleus accumbens, left (IC24) | 0 | 0.04 | <0.001 |
Somatosensory cortex (IC30) ↔ insular cortex, and motor cortex (IC35) | 0 | 0.53 | <0.001 |
Olfactory bulb (IC38) ↔ medulla (IC2) | 0 | 0.28 | 0.003 |
Cerebellum (IC1) ↔ nucleus accumbens, left (IC24) | 0 | 0.23 | 0.005 |
Increased by VPA treatment | VPA-treated | Control | |
Olfactory bulb (IC38) ↔ orbitofrontal cortex, and cerebellum (IC10) | 0.33 | 0 | <0.001 |
Decreased in males | Male | Female | |
Visual cortex (IC5) ↔ auditory cortex (IC12) | 0 | 0.61 | <0.001 |
Orbitofrontal cortex, right, and caudoputamen, right (IC26) ↔ caudoputamen, and olfactory bulb, left (IC28) | 0 | 0.56 | 0.003 |
Olfactory bulb, right, and caudoputamen, right (IC14) ↔ cingulate cortex, and cerebellum, left (IC15) | 0 | 0.62 | 0.004 |
More increased in males than in females by VPA treatment: [(male − female) × (VPA-treated - control)] | Male | Female | |
Anterodorsal hippocampus (IC6) ↔ caudoputamen (IC21) | 0.43 | 0 | <0.001 |
Medulla (IC2) ↔ insular cortex, and motor cortex (IC35) | 0.31 | 0 | <0.001 |
Less increased in males than in females by VPA treatment: [(female − male) × (VPA-treated - control)] | Male | Female | |
Retrosplenial cortex (IC17) ↔ nucleus accumbens, right, and orbitofrontal cortex, right (IC25) | 0 | 0.55 | 0.003 |
Visual cortex (IC5) ↔ cingulate cortex, and cerebellum, left (IC15) | 0 | 0.32 | 0.005 |
Superior and inferior colliculus, left, and retrosplenial cortex (IC11) ↔ caudoputamen, and olfactory bulb, left (IC28) | 0 | 0.40 | 0.01 |
A FDR ≤0.05 was considered as statistically significant. VPA, valproic acid; IC. Independent component.